Kevin Feeley Sells 3,728 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,728 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $76.75, for a total value of $286,124.00. Following the completion of the sale, the chief financial officer now directly owns 28,200 shares in the company, valued at approximately $2,164,350. This trade represents a 11.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $18,248.40.

GeneDx Price Performance

NASDAQ WGS opened at $75.30 on Friday. The firm has a market capitalization of $2.07 billion, a PE ratio of -24.21 and a beta of 2.03. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a 12 month low of $2.11 and a 12 month high of $89.11. The company’s 50 day simple moving average is $72.11 and its 200 day simple moving average is $46.96.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. During the same quarter in the previous year, the business earned ($0.82) EPS. The company’s quarterly revenue was up 44.3% compared to the same quarter last year. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the subject of several analyst reports. Wells Fargo & Company boosted their price objective on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum increased their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $59.33.

Institutional Investors Weigh In On GeneDx

Institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in shares of GeneDx in the 2nd quarter worth approximately $34,000. nVerses Capital LLC acquired a new position in GeneDx in the second quarter worth approximately $50,000. CWM LLC bought a new position in shares of GeneDx in the third quarter valued at $89,000. SG Americas Securities LLC acquired a new stake in shares of GeneDx during the 3rd quarter valued at $198,000. Finally, Point72 DIFC Ltd bought a new stake in shares of GeneDx during the 3rd quarter worth $220,000. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.